Advair's throne is slowly eroding. With stepped-up competition from rival lung drugs--including AstraZeneca's ($AZN) Symbicort--GlaxoSmithKline's ($GSK) top-selling ...
BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient share of ...
The government is taking steps to curb use of some long-acting asthma drugs taken by millions, issuing safety restrictions Thursday to lower an uncommon but potentially life-threatening risk that ...
AstraZeneca's assault on GlaxoSmithKline’s position as the company selling the most-prescribed combination respiratory drug received a boost yesterday when it presented clinical data claiming ...
Nycomed, which is in the process of being acquired by Takeda, and Finland's Orion Corp, are looking to co-market generics of two respiratory blockbusters - GlaxoSmithKline's Advair and AstraZeneca's ...
LargePharma_SymbicortAstraZeneca’s Symbicort, the second-to-market ICS/LABA combo behind GlaxoSmithKline’s Advair, faced an uphill battle on its launch in June 2007, squaring off against a firmly ...
On November 18, 2005, FDA alerted health care professionals and patients that several long-acting bronchodilator medicines have been associated with possible increased risk of worsening wheezing ...
This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. Asthma patients should not take inhalable long-acting beta-agonists such ...
WASHINGTON — Two federal drug officials have concluded that asthma patients risk death if they continue to use four hugely popular asthma drugs: Advair, Symbicort, Serevent and Foradil. But the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results